Literature DB >> 15305880

Regulation of striatal tyrosine hydroxylase phosphorylation by acute and chronic haloperidol.

Kerstin Håkansson1, Laura Pozzi, Alessandro Usiello, John Haycock, Emiliana Borrelli, Gilberto Fisone.   

Abstract

The typical neuroleptic haloperidol increases the state of phosphorylation and activity of tyrosine hydroxylase (TH), the rate-limiting enzyme in the synthesis of catecholamines. Here we show that the increases in TH phosphorylation produced by haloperidol at Ser31 and Ser40, two sites critically involved in the regulation of enzymatic activity, are abolished in dopamine D2 receptor-null mice and mimicked by the selective dopamine D2 receptor antagonist, eticlopride. Moreover, the ability of haloperidol and eticlopride to stimulate phosphorylation at both seryl residues is prevented by treatment with SL327, a compound that blocks activation of extracellular signal-regulated protein kinases 1 and 2 (ERK1/2). We also show that chronic administration of haloperidol reduces the basal levels of phosphoSer31-TH and decreases the ability of the drug to stimulate Ser40 phosphorylation. These results provide a model accounting for the stimulation exerted by haloperidol on dopamine synthesis. According to this model, haloperidol increases TH activity via blockade of dopamine D2 receptors, disinhibition of dopaminergic projection neurons and ERK1/2-dependent phosphorylation of TH at Ser31 and Ser40. These studies also show that lower levels of phosphorylated TH are associated with chronic neuroleptic treatment and may be related to depressed dopaminergic transmission in nigrostriatal neurons.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15305880     DOI: 10.1111/j.1460-9568.2004.03547.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  17 in total

1.  Role of aberrant striatal dopamine D1 receptor/cAMP/protein kinase A/DARPP32 signaling in the paradoxical calming effect of amphetamine.

Authors:  Francesco Napolitano; Alessandra Bonito-Oliva; Mauro Federici; Manolo Carta; Francesco Errico; Salvatore Magara; Giuseppina Martella; Robert Nisticò; Diego Centonze; Antonio Pisani; Howard H Gu; Nicola B Mercuri; Alessandro Usiello
Journal:  J Neurosci       Date:  2010-08-18       Impact factor: 6.167

2.  Implication of the ERK/MAPK pathway in antipsychotics-induced dopamine D2 receptor upregulation and in the preventive effects of (±)-α-lipoic acid in SH-SY5Y neuroblastoma cells.

Authors:  Jessica Deslauriers; Christian Desmarais; Philippe Sarret; Sylvain Grignon
Journal:  J Mol Neurosci       Date:  2013-11-08       Impact factor: 3.444

3.  Sensitized nucleus accumbens dopamine terminal responses to methylphenidate and dopamine transporter releasers after intermittent-access self-administration.

Authors:  Erin S Calipari; Sara R Jones
Journal:  Neuropharmacology       Date:  2014-03-13       Impact factor: 5.250

4.  Dual control of dopamine synthesis and release by presynaptic and postsynaptic dopamine D2 receptors.

Authors:  Andrea Anzalone; José E Lizardi-Ortiz; Maria Ramos; Claudia De Mei; F Woodward Hopf; Ciro Iaccarino; Briac Halbout; Jacob Jacobsen; Chisato Kinoshita; Marc Welter; Marc G Caron; Antonello Bonci; David Sulzer; Emiliana Borrelli
Journal:  J Neurosci       Date:  2012-06-27       Impact factor: 6.167

5.  Proteomic and genomic evidence implicates the postsynaptic density in schizophrenia.

Authors:  M Föcking; L M Lopez; J A English; P Dicker; A Wolff; E Brindley; K Wynne; G Cagney; D R Cotter
Journal:  Mol Psychiatry       Date:  2014-07-22       Impact factor: 15.992

6.  Dopamine D2 receptor dysfunction is rescued by adenosine A2A receptor antagonism in a model of DYT1 dystonia.

Authors:  Francesco Napolitano; Massimo Pasqualetti; Alessandro Usiello; Emanuela Santini; Giulia Pacini; Giuseppe Sciamanna; Francesco Errico; Annalisa Tassone; Valeria Di Dato; Giuseppina Martella; Dario Cuomo; Gilberto Fisone; Giorgio Bernardi; Georgia Mandolesi; Nicola B Mercuri; David G Standaert; Antonio Pisani
Journal:  Neurobiol Dis       Date:  2010-03-19       Impact factor: 5.996

7.  Dopamine and serotonin metabolism in response to chronic administration of fluvoxamine and haloperidol combined treatment.

Authors:  Y Chertkow; O Weinreb; M B H Youdim; H Silver
Journal:  J Neural Transm (Vienna)       Date:  2007-06-18       Impact factor: 3.575

8.  Regulation of Tyrosine Hydroxylase Expression and Phosphorylation in Dopamine Transporter-Deficient Mice.

Authors:  Michael F Salvatore; Erin S Calipari; Sara R Jones
Journal:  ACS Chem Neurosci       Date:  2016-05-10       Impact factor: 4.418

9.  Opposing patterns of signaling activation in dopamine D1 and D2 receptor-expressing striatal neurons in response to cocaine and haloperidol.

Authors:  Jesus Bertran-Gonzalez; Clémentine Bosch; Matthieu Maroteaux; Miriam Matamales; Denis Hervé; Emmanuel Valjent; Jean-Antoine Girault
Journal:  J Neurosci       Date:  2008-05-28       Impact factor: 6.167

10.  No Evidence for Association between Tyrosine Hydroxylase Gene Val81Met Polymorphism and Susceptibility to Tardive Dyskinesia in Schizophrenia.

Authors:  Heon-Jeong Lee; Seung-Gul Kang; Jung-Eun Choi; Young-Min Park; Se-Won Lim; Min Kyu Rhee; Seung-Hyun Kim; Leen Kim
Journal:  Psychiatry Investig       Date:  2009-06-30       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.